Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial

IMPORTANCE: The 2-year efficacy and safety of combination therapy of ranibizumab administered together with verteporfin photodynamic therapy (vPDT) compared with ranibizumab monotherapy in participants with polypoidal choroidal vasculopathy (PCV) are unclear. OBJECTIVE: To compare treatment outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Tock H., Lai, Timothy Y. Y., Takahashi, Kanji, Wong, Tien Y., Chen, Lee-Jen, Ruamviboonsuk, Paisan, Tan, Colin S., Lee, Won Ki, Cheung, Chui Ming Gemmy, Ngah, Nor Fariza, Patalauskaite, Ramune, Margaron, Philippe, Koh, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366282/
https://www.ncbi.nlm.nih.gov/pubmed/32672800
http://dx.doi.org/10.1001/jamaophthalmol.2020.2443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366282/
https://www.ncbi.nlm.nih.gov/pubmed/32672800
http://dx.doi.org/10.1001/jamaophthalmol.2020.2443

Ejemplares similares